Perception vs. Perspective: Rethinking AI Adoption in Biopharma

Introduction:

In this episode, we explore the gap between how AI is perceived and how it is actually adopted in biopharma. While AI continues to generate excitement across the industry, real-world implementation often reveals challenges around execution, governance, and trust.

Host Jane Urban CDAO at Improzo sits down with Navdeep Singh, Customer Success Leader at AWS to break down what it truly takes to move past pilots and build scalable, execution-focused AI adoption across commercial and medical workflows.

Key Highlights

• AI adoption challenges are often operational, not technical.
  Organizations rarely struggle with models, they struggle with embedding AI into real workflows where decisions are made. This often creates gaps between what AI can do and what teams are actually able to execute day to day.
• The gap between perception and reality is widening.
  While AI is often positioned as transformative, many teams face friction when translating that potential into day-to-day execution. Expectations move faster than systems, processes, and teams can realistically adapt.
• Context is critical for decision-making.
  AI systems must operate with a clear understanding of business context, data relationships, and real-world constraints to be effective. Without this, even accurate outputs can fail to translate into meaningful action.
• Governance builds trust in AI systems.
  Explainability, accountability, and clear decision ownership are essential for adoption especially in regulated environments like life sciences. Teams need to understand not just what the system suggests, but why it suggests it.
• Moving beyond pilots requires execution focus.
  Successful organizations are those that move from experimentation to embedding AI into core processes and workflows. This shift is what separates isolated success from scalable impact.
• Human judgment remains central.
  AI can accelerate insights, but decisions still require human context, interpretation, and accountability. The most effective models are those that augment, not replace, human thinking.
• Adoption is a journey, not a switch.
  Organizations evolve through stages from assisted decision-making to more embedded, intelligent execution over time. Each stage builds confidence, capability, and alignment across teams.
• AI works best when it fits into existing systems.
  Embedding intelligence into tools teams already use drives adoption far more effectively than introducing standalone platforms. Familiar environments reduce friction and make it easier for teams to act on insights.
• Real impact comes from clarity, not complexity.
  Simplifying how decisions are supported often delivers more value than adding more tools or layers of technology. Clarity enables faster action, better alignment, and more consistent outcomes.

Final takeaway:

AI adoption in biopharma isn’t just about capability, it’s about perspective. Organizations that focus on embedding AI into real workflows, with clarity, governance, and human oversight, will be the ones that turn potential into measurable impact.